Free Trial
NASDAQ:AUPH

Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

Aurinia Pharmaceuticals logo
$7.90 -0.09 (-1.06%)
As of 03:13 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH)

Key Stats

Today's Range
$7.77
$7.97
50-Day Range
$7.20
$8.67
52-Week Range
$5.15
$10.67
Volume
621,148 shs
Average Volume
1.33 million shs
Market Capitalization
$1.07 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Consensus Rating
Buy

Company Overview

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
68th Percentile Overall Score

AUPH MarketRank™: 

Aurinia Pharmaceuticals scored higher than 68% of companies evaluated by MarketBeat, and ranked 335th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Aurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Aurinia Pharmaceuticals has received no research coverage in the past 90 days.

  • Read more about Aurinia Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Aurinia Pharmaceuticals is -52.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Aurinia Pharmaceuticals is -52.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Aurinia Pharmaceuticals has a P/B Ratio of 3.01. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Aurinia Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    9.06% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 3.29%, indicating that investor sentiment is improving.
  • Dividend Yield

    Aurinia Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Aurinia Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.06% of the float of Aurinia Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Aurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.5.
  • Change versus previous month

    Short interest in Aurinia Pharmaceuticals has recently decreased by 3.29%, indicating that investor sentiment is improving.
  • News Sentiment

    Aurinia Pharmaceuticals has a news sentiment score of 1.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 6 news articles for Aurinia Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    33 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 65% compared to the previous 30 days.
  • MarketBeat Follows

    2 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Aurinia Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,753,094.00 in company stock.

  • Percentage Held by Insiders

    12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.

  • Read more about Aurinia Pharmaceuticals' insider trading history.
Receive AUPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AUPH Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
See More Headlines

AUPH Stock Analysis - Frequently Asked Questions

Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH stock has decreased by 11.9% and is now trading at $7.9150.
View the best growth stocks for 2025 here
.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) posted its quarterly earnings results on Monday, May, 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts' consensus estimates of $0.08 by $0.08. The biotechnology company earned $62.47 million during the quarter, compared to the consensus estimate of $61.06 million. Aurinia Pharmaceuticals had a negative net margin of 10.23% and a negative trailing twelve-month return on equity of 4.41%.
Read the conference call transcript
.

Top institutional shareholders of Aurinia Pharmaceuticals include Armistice Capital LLC (3.66%), Goldman Sachs Group Inc. (1.19%), Nuveen LLC (0.91%) and Jupiter Asset Management Ltd. (0.55%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, George M Milne Jr, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan.
View institutional ownership trends
.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC).

Company Calendar

Last Earnings
5/12/2025
Today
5/30/2025
Next Earnings (Estimated)
8/07/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AUPH
Employees
300
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$11.50
High Stock Price Target
$13.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+43.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
72.64
P/E Growth
N/A
Net Income
-$78.02 million
Pretax Margin
-9.14%

Debt

Sales & Book Value

Annual Sales
$247.30 million
Price / Cash Flow
N/A
Book Value
$2.63 per share
Price / Book
3.04

Miscellaneous

Free Float
137,022,000
Market Cap
$1.08 billion
Optionable
Optionable
Beta
1.16

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (NASDAQ:AUPH) was last updated on 5/30/2025 by MarketBeat.com Staff
From Our Partners